Global Study Associate Director

Inside AstraZeneca's 2026 ISPE Facility of the Year Awards (FOYA) Social Impact - Unmet Medical Needs Category award-winning project: Commercial Cell Therapy Facility. AstraZeneca's Commercial Cell Therapy Facility in Rockville, Maryland is setting a new benchmark for how pharmaceutical manufacturers can deliver lifesaving therapies while simultaneously advancing sustainability and operational excellence. Recognized as the 2026 ISPE Facility of the Year Awards (FOYA) Social Impact - Unmet Medical Needs Category Winner, the facility demonstrates how innovative engineering, risk-based design, and patient-centered thinking can transform commercial cell therapy manufacturing. Spanning 105,000 square feet across three stories, the fully electrified biomanufacturing facility was designed to support commercial-scale autologous T-cell therapy manufacturing and late-stage oncology clinical trials. More importantly, it was built around a singular mission: ensuring uninterrupted access to potentially lifesaving therapies for patients facing some of the most serious unmet medical needs in healthcare today. Why AstraZeneca won. Autologous cell therapies present unique manufacturing challenges unlike those found in traditional pharmaceutical production. Because each therapy is manufactured from an individual patient's own cells, every batch is personalized and irreplaceable. Unlike conventional medicines, inventory cannot be stockpiled for future use. If manufacturing is interrupted, the consequences may extend far beyond production delays. For many cell therapy patients, particularly those battling advanced cancers, treatment timelines are often measured in weeks or months. A manufacturing failure that compromises a patient-specific batch can eliminate a critical treatment opportunity at a moment when time is limited. Recognizing these realities, AstraZeneca established an ambitious and nonnegotiable design objective for its Rockville facility: 100 percent operational uptime with no facility-wide maintenance shutdowns. This requirement fundamentally shaped the project's design philosophy. Rather than relying on traditional pharmaceutical manufacturing standards alone, AstraZeneca and its project partners drew inspiration from industries where continuous operation is essential, including nuclear power generation, oil refining, and Tier IV data center infrastructure. The result is a facility engineered to achieve an extraordinarily high level of reliability. Through the application of quantitative risk assessments and layers of protection analysis, the team designed a system with a probability of total power loss of less than one event in 10,000 years. This achievement establishes a new reliability benchmark for commercial cell therapy manufacturing and reflects a deep commitment to protecting each patient's individualized treatment journey. Engineering resiliency around the patient. At the heart of the project is an important shift in perspective: every batch represents a patient. This patient-first philosophy influenced every aspect of facility design. The team systematically identified and eliminated single points of failure across critical infrastructure systems, including: * Electrical distribution systems * Mechanical infrastructure * Automation platforms * Process utilities * Building operations systems By creating redundancy throughout the facility, AstraZeneca significantly reduced the likelihood that infrastructure failures could disrupt manufacturing operations or jeopardize in-process therapies. The facility is designed to support treatment production for up to 4,000 patients annually, creating the capacity needed to bring personalized cancer therapies to a larger patient population while maintaining the reliability required for commercial-scale operations. The significance of this accomplishment extends beyond engineering. It represents a tangible investment in patient outcomes, helping ensure that individuals facing life-threatening diseases have reliable access to therapies that could improve or extend their lives. Redefining the relationship between resiliency and sustainability. Historically, highly resilient facilities have often relied on energy-intensive designs that increase environmental impact. AstraZeneca challenged this long-standing assumption. The Rockville facility demonstrates that operational resiliency and environmental stewardship can be complementary objectives rather than competing priorities. As a fully electrified biomanufacturing facility, the project was designed to support net-zero operational carbon performance while delivering exceptional reliability. The facility achieved: * A 50 percent reduction in energy consumption * A 50 percent reduction in water use * Net-zero operational carbon objectives * Fully electrified building systems These sustainability achievements are particularly noteworthy given the complexity and criticality of cell therapy manufacturing. The facility successfully combines advanced resiliency measures with resource-efficient technologies, creating a model that addresses both patient needs and broader environmental responsibilities. By proving that world-class reliability can coexist with aggressive sustainability goals, AstraZeneca has established a new paradigm for future pharmaceutical manufacturing facilities. A replicable blueprint for the Future of Cell Therapy manufacturing. Beyond its immediate operational impact, the Rockville facility serves as a model for the broader life sciences industry. The project successfully integrates cross-industry risk methodologies, advanced infrastructure design principles, and sustainable operating strategies into a scalable commercial manufacturing platform. These innovations create a framework that other organizations can adapt as demand for personalized medicines continues to grow. The facility demonstrates that patient-centered manufacturing can be achieved at commercial scale without compromising sustainability, operational performance, or long-term business viability. As cell and gene therapies continue to reshape modern healthcare, manufacturers face increasing pressure to deliver highly personalized treatments reliably, efficiently, and responsibly. AstraZeneca's project provides a practical roadmap for meeting those expectations. Most importantly, the facility reinforces a powerful message: protecting patients and protecting the planet can be achieved simultaneously through thoughtful design, innovation, and execution. A new standard for Social Impact in pharmaceutical manufacturing. By earning 2026 ISPE FOYA Social Impact - Unmet Medical Needs Category Winner recognition, AstraZeneca has demonstrated how innovative facility design can directly support better patient outcomes while advancing sustainability goals. The Commercial Cell Therapy Facility is more than a manufacturing plant. It is a patient-centered infrastructure platform engineered to protect every personalized therapy, eliminate avoidable interruptions, and ensure reliable access to potentially lifesaving treatments. Through unprecedented reliability standards, industry-leading sustainability performance, and a commitment to addressing unmet medical needs, AstraZeneca has established a new benchmark for commercial cell therapy manufacturing. As personalized medicines continue to transform healthcare, facilities like the Rockville site will play a critical role in ensuring patients receive the therapies they need without delay. AstraZeneca's award-winning project serves as a compelling example of how innovation, resiliency, and social responsibility can come together to create lasting impact for patients, communities, and the pharmaceutical industry as a whole.> ISPE Shape the Future of Pharma ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.

The European Union has approved Enhertu (trastuzumab deruxtecan) combined with pertuzumab as first-line treatment for HER2 positive metastatic breast cancer, marking the first new regimen in this setting in over a decade. The treatment, jointly developed by Daiichi Sankyo and AstraZeneca, is based on the DESTINY-Breast09 phase 3 trial. The trial showed the combination reduced disease progression or death risk by 44% compared to standard treatment. Median progression-free survival reached 40.7 months versus 26.9 months with conventional therapy. The European Commission approval follows a recent tumour agnostic approval for Enhertu in the EU. AstraZeneca will pay Daiichi Sankyo a $100 million milestone payment for this indication. The combination is now approved in over 40 countries worldwide for first-line treatment of HER2 positive metastatic breast cancer.

From Oxfordshire to Wales: where UK Life Sciences investment is going in 2026. Cambridge is one of several UK life sciences hubs attracting new investment in R&D, manufacturing and biopharma infrastructure. From clinical cleanrooms in Birmingham to mRNA manufacturing in Oxfordshire, new investment is adding research and production capacity across the UK life sciences sector. The UK life sciences sector generates approximately $200 billion (£147 billion) in annual turnover and employs around 360,000 people. Nearly half of these jobs are located outside London, the East and South East of England. In July 2026, the UK government reported that the country had attracted more than $4.1 billion (£3 billion) in public-private life sciences investment over the previous 12 months. Pharma investment reaches Cambridge, Oxfordshire and surrey. AstraZeneca is investing approximately $408 million (£300 million) across its Cambridge headquarters and Macclesfield operations, including work using AI in drug discovery. Moderna has also opened its Innovation and Technology Centre at Harwell in Oxfordshire as part of its 10-year, around $1.36 billion (£1 billion) UK R&D commitment. The site combines clinical R&D with mRNA drug substance manufacturing and has capacity to produce up to 100 million vaccine doses during endemic periods, rising to 250 million during a pandemic. Around $680 million (£500 million) is being invested in UCB's new R&D and biologics manufacturing facility in Windlesham. The project is expected to support up to 240 jobs. Xtalks Insights Protected by reCAPTCHA. What topics would you like to hear more about? Select all that apply. Want to get even more specific? Help us narrow down the sub-topics that you're most interested in. For webinars, videos, podcasts and more from Xtalks, join our community today. Manufacturing investment extends across the UK. In April 2026, the UK government announced more than $109 million (£80 million) in investment across several life sciences manufacturing projects. Accord Healthcare is investing more than $61 million (£45 million) in Barnstaple, North Devon, to increase local production of newer medicines, including treatments for bipolar disorder, while maintaining its generic medicine operations. In Birmingham, approximately $13.6 million (£10 million) is going toward a near-patient biomanufacturing facility at the Precision Health Technologies Accelerator. The site will include three cleanrooms for medicines, vaccines and clinical trial materials, including cell and gene therapies and mRNA vaccines. In Wales, specialty pharmaceutical company Norgine is investing more than $27 million (£20 million) at its Hengoed site to expand production of gastrointestinal medicines and upgrade manufacturing capacity. Public investment is also being used to bring in private capital. The government says around $156 million (£115 million) allocated through the Life Sciences Innovative Manufacturing Fund has helped secure more than $894 million (£657 million) in private investment across 10 projects. Those projects are expected to create 487 jobs and safeguard another 1,330. In August 2026, the UK government released eligibility rules for its Life Sciences Large Investment Portfolio to encourage major life sciences projects in the country. To qualify for support, companies must plan to invest at least $340 million (£250 million) in UK-based R&D or manufacturing over three years, with at least one eligible project beginning within 12 months. If you want your company to be featured on Xtalks.com, please email [email protected].